← All trials
NCT03873727
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2019
- Primary completion
- Apr 30, 2023
- Completion date
- Oct 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 56
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Assistance Publique - Hôpitaux de ParisLead sponsor
- University of ParisOverall official - principal investigator
- CHU Henri MondorOverall official - principal investigator
- Robert Ballanger Intercommunity Hospital CenterOverall official - principal investigator
- Innovative clinical research network in vaccinology (I-REIVAC)Collaborator
- EUCLIDCollaborator
- University of LyonOverall official - principal investigator
- University of ParisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.